{
  "docId": "019de073-742c-704c-a810-4500da4f1d81",
  "docSlug": "e78883ddf681fdb15564423388c7a078",
  "documentTitle": "Allarity Therapeutics | Investor Conference Presentation Deck | 23 slides",
  "authorId": "allarity-therapeutics",
  "authorName": "Allarity Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 23,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "propose_solution",
  "function": "quantify_opportunity",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes a stacked bar chart showing market growth projections for ovarian and pancreatic cancer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-742c-704c-a810-4500da4f1d81/11",
  "deckHref": "/decks/019de073-742c-704c-a810-4500da4f1d81",
  "deckJsonHref": "/decks/019de073-742c-704c-a810-4500da4f1d81.json",
  "deckAnchorHref": "/decks/019de073-742c-704c-a810-4500da4f1d81#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Potential Synergistic Therapeutic Benefit of Dovitinib + Stenoparib in 2nd line or later Ovarian Cancer Initiation of Phase 1b Dosing Study Anticipated by Early Q4 2022",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67a6cbdb-0601-4530-8056-5d2d3581c499",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.35,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "chart",
      "text": "Annual sales (US$m) in indications targeted by Stenoparib with DRP",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5198b0b2-2d8c-411c-99d7-7dc205ee761b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.5,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "list",
      "text": "Treatment setting = 2nd line or later therapy in ovarian cancer (OC). Prior clinical trials have shown promising synergy between PARPi and TKIs. Stenoparib has shown promising monotherapy activity. Validated DRPs will be used to select responders. Global PARP market projected to reach $9B by 2027. DRP on label allows for pricing premium. Potential to expand to pancreatic cancer.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8c81869-1ebb-4fef-a279-e49ebb985030",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. PARP = Poly ADP-Ribose Polymerase... 2. Under Eisai, stenoparib (ZX-121) was formally known as E7449",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3626f0b4-4739-46b8-872b-f79c898f5c96",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Dovitinib: Combination Therapy Opportunity with Stenoparib (PARPi)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "adc65225-5f89-4418-b7c6-a39e06d6e9d4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 10,
      "beatId": "b256bbaf-5ead-4fee-9327-1e3695ac93a7",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation presents DRP as a solution to the problem, highlighting its potential to personalize cancer care and improve patient outcomes.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}